Myeloperoxidase and paraoxonase-1 in type 2 diabetic patients

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 19, Issue 9, 2009, Pages 613-619

  Jornayvaz, F R ^a   Brulhart Meynet, M C ^a   James, R W ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Cardiovascular risk; High density lipoproteins; Oxidative stress

Indexed keywords

APOA1 PROTEIN, HUMAN; APOLIPOPROTEIN A1; ARYLDIALKYLPHOSPHATASE; HIGH DENSITY LIPOPROTEIN; PEROXIDASE; PON1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BLOOD; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; ENZYME ACTIVATION; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PHYSIOLOGY; PREDICTION AND FORECASTING; RISK FACTOR;

ADULT; AGED; APOLIPOPROTEIN A-I; ARYLDIALKYLPHOSPHATASE; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; ENZYME ACTIVATION; FEMALE; HUMANS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OXIDATIVE STRESS; PEROXIDASE; PREDICTIVE VALUE OF TESTS; RISK FACTORS;

EID: 70350752361     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2008.12.005     Document Type: Article

References (28)

1. Assmann G., and Nofer J.R. Atheroprotective effects of high-density lipoproteins. Annu Rev Med 54 (2003) 321-341
2. Shao B., Oda M.N., Oram J.F., and Heinecke J.W. Myeloperoxidase: an inflammatory enzyme for generating dysfunctional high density lipoprotein. Curr Opin Cardiol 21 (2006) 322-328
3. Bergt C., Pennathur S., Fu X., Byun J., O'Brien K., McDonald T.O., et al. The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc Natl Acad Sci USA 101 (2004) 13032-13037
4. Marsche G., Hammer A., Oskolkova O., Kozarsky K.F., Sattler W., and Malle E. Hypochlorite-modified high density lipoprotein, a high affinity ligand to scavenger receptor class B, type I, impairs high density lipoprotein-dependent selective lipid uptake and reverse cholesterol transport. J Biol Chem 277 (2002) 32172-32179
5. Brennan M.L., Penn M.S., Van Lente F., Nambi V., Shishehbor M.H., Aviles R.J., et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 349 (2003) 1595-1604
6. Meuwese M.C., Stroes E.S., Hazen S.L., van Miert J.N., Kuivenhoven J.A., Schaub R.G., et al. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol 50 (2007) 159-165
7. Mocatta T.J., Pilbrow A.P., Cameron V.A., Senthilmohan R., Frampton C.M., Richards A.M., et al. Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction. J Am Coll Cardiol 49 (2007) 1993-2000
8. Madamanchi N.R., Vendrov A., and Runge M.S. Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol 25 (2005) 29-38
9. Bhattacharyya T., Nicholls S.J., Topol E.J., Zhang R., Yang X., Schmitt D., et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 299 (2008) 1265-1276
10. Deakin S.P., and James R.W. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. Clin Sci 107 (2004) 435-447
11. Deakin S., Moren X., and James R.W. HDL oxidation compromises its influence on paraoxonase-1 secretion and its capacity to modulate enzyme activity. Arterioscler Thromb Vasc Biol 27 (2007) 1146-1152
12. West I.C. Radicals and oxidative stress in diabetes. Diabet Med 17 (2000) 171-180
13. Boemi M., Sirolla C., Testa R., Cenerelli S., Fumelli P., and James R.W. Smoking is associated with reduced serum levels of the antioxidant enzyme, paraoxonase, in Type 2 diabetic patients. Diabet Med 21 (2004) 423-427
14. Mackness B., Mackness M.I., Arrol S., Turkie W., Julier K., Abuasha B., et al. Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis 139 (1998) 341-349
15. James R.W., Leviev I., and Righetti A. Smoking is associated with reduced serum paraoxonase activity and concentration in coronary artery disease patients. Circulation 101 (2000) 2252-2257
16. Leviev I., Righetti A., and James R.W. Paraoxonase promoter polymorphism T(-107)C and relative paraoxonase deficiency as determinants of risk of coronary artery disease. J Mol Med 79 (2001) 457-463
17. James R.W., and Pometta D. Differences in lipoprotein subfraction composition and distribution between type 1 diabetic men and control subjects. Diabetes 39 (1990) 1158-1164
18. James R.W., and Pometta D. The distribution profiles of very low density and low density lipoproteins in poorly-controlled male, type 2 (non-insulin-dependent) diabetic patients. Diabetologia 34 (1991) 246-252
19. James R.W., and Pometta D. Immunfractionation of high-density lipoprotein subclasses 2 and 3: similarities and differences of fractions isolated from male and female populations. Atherosclerosis 83 (1990) 35-45
20. Blatter Garin M.-C., Abbot C., Messmer S., Mackness M.I., Durrington P., Pometta D., et al. Quantification of human serum paraoxonase by enzyme-linked immunoassay: population differences in protein concentrations. Biochem J 304 (1994) 549-554
21. Durrington P.N., Mackness B., and Mackness M.I. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 21 (2001) 473-480
22. Robertson R.P., Harmon J., Tran P.O., and Poitout V. Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes 53 Suppl (2004) S119-S124
23. Brennan M.L., and Hazen S.L. Emerging role of myeloperoxidase and oxidant stress markers in cardiovascular risk assessment. Curr Opin Lipidol 14 (2003) 353-359
24. Schindhelm R.K., Alssema M., Diamant M., Teerlink T., Dekker J.M., Kok A., et al. Comparison of two consecutive fat-rich and carbohydrate-rich meals on postprandial myeloperoxidase response in women with and without type 2 diabetes mellitus. Metabolism 57 (2008) 262-267
25. Klebanoff S.J. Myeloperoxidase: friend and foe. J Leukoc Biol 77 (2005) 598-625
26. Marsche G., Furtmüller P.G., Obinger C., Sattler W., and Malle E. Hypochlorite-modified high-density lipoprotein acts as a sink for myeloperoxidase in vitro. Cardiovasc Res 79 (2008) 187-194
27. Cabana V.G., Reardon C.A., Feng N., Neath S., Lukens J., and Getz G.S. Serum paraoxonase: effect of the apolipoprotein composition of HDL and the acute phase response. J Lipid Res 44 (2003) 780-792
28. Nicholls S.J., Zheng L., and Hazen S.L. Formation of dysfunctional high-density lipoprotein by myeloperoxidase. Trends Cardiovasc Med 15 (2005) 212-219